Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

BackgroundThe frequency of epidermal growth factor receptor (EGFR) mutations and the efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung squamous cell carcinoma (SCC) are unknown. This study was designed to investigate the incidence of EGFR mutations and the role of targ...

Full description

Bibliographic Details
Main Authors:	Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang, Tianqing Chu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Subjects:	female lung cancer squamous cell carcinoma epidermal growth factor receptor tyrosine kinase inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.652560/full

Similar Items

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
by: Rajesh Kota, et al.
Published: (2015-01-01)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Katsuhiro Masago, et al.
Published: (2018-01-01)

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
by: Chang H, et al.
Published: (2016-08-01)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
by: Sojung Park, et al.
Published: (2021-01-01)

Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
by: Philomena Charlotte Dsouza, et al.
Published: (2017-01-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma
by: Manoj Kumar Kashyap, et al.
Published: (2018-02-01)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
by: Tristan A. Barnes, et al.
Published: (2017-05-01)

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
by: Chia-Yu Chu, et al.
Published: (2017-06-01)

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
by: Zhang H
Published: (2016-11-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
by: Fan L, et al.
Published: (2017-01-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR‐mutated lung adenocarcinoma: a report of two cases
by: Hironori Uruga, et al.
Published: (2020-03-01)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
by: Liang H, et al.
Published: (2018-09-01)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
by: Zhou S, et al.
Published: (2019-10-01)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
by: Lee CS, et al.
Published: (2020-10-01)

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer
by: Chunsun LI, et al.
Published: (2010-01-01)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
by: Nobuaki Kobayashi, et al.
Published: (2021-04-01)

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy
by: Panpan Lv, et al.
Published: (2020-01-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
by: Rui Jin, et al.
Published: (2021-06-01)

Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations
by: Qunhui WANG, et al.
Published: (2016-08-01)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

The Relationship between EGFR Mutations and Response and Prognosis of Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
by: Xuebing LI, et al.
Published: (2008-04-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
by: Javier Torres-Jiménez, et al.
Published: (2021-01-01)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Chai CS, et al.
Published: (2020-07-01)

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study
by: John WC Chang, et al.
Published: (2015-06-01)

Tyrosine Kinase Receptors in Oncology
by: Jorge Esteban-Villarrubia, et al.
Published: (2020-11-01)

Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer
by: Hongjian Li, et al.
Published: (2017-11-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review
by: Han BH, et al.
Published: (2018-04-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
by: Zuoquan Zhu, et al.
Published: (2021-05-01)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI ) rechallenge in small cell transformation after EGFR-TKI failure: a case report
by: Lee S, et al.
Published: (2018-07-01)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease
by: Young Hak Kim, et al.
Published: (2011-09-01)